David A. Cooper

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Roy T. Steigbigel, David A. Cooper, Princy Kumar et al. · New England Journal of Medicine · 2008 · 683 citations · Full text

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Adriano Lazzarin, Bonaventura Clotet, David A. Cooper et al. · New England Journal of Medicine · 2003 · 651 citations · Full text

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

Sven A. Danner, Andrew Carr, John M. Leonard et al. · New England Journal of Medicine · 1995 · 569 citations · Full text

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

David A. Cooper, Roy T. Steigbigel, José M. Gatell et al. · New England Journal of Medicine · 2008 · 505 citations · Full text

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Treatment And Prevention, Week 48, Antiviral Drug Development +9